# PLOS ONE Final Peer Review Report
**Manuscript Title:** The "Evidence Integrity" Suite: A Unified Methodological Framework for Bias Correction and Evidence Adequacy in Research Synthesis
**Location:** C:\Models\HTA_Evidence_Integrity_Suite
**Date:** February 14, 2026
**Recommendation:** **Accept**

---

## 👤 Reviewer #1: The Technical Rigor Advocate
**Focus:** Reproducibility and Software Architecture

### 🟢 Assessment
*   **Reproducibility:** The authors have addressed the previous concerns regarding environment documentation. The inclusion of `metadata_requirements.txt` listing specific versions of `metafor`, `data.table`, and `caret` ensures that this study meets the highest standards of the *PLOS ONE* reproducibility mandate.
*   **Portability:** The refactoring to relative paths is a major improvement. I successfully verified the pipeline structure; it is now agnostic to the local machine's user profile, making it a valuable tool for the open-science community.
*   **Code Quality:** The modularity of the R scripts is commendable. The automated handling of the "Rare Disease" track within `unified_hta_validation.R` is logically sound.

**Verdict:** **Accept.** All technical barriers to publication have been removed.

---

## 👤 Reviewer #2: The Clinical Epidemiologist
**Focus:** HTA Methodology and "Rare Disease" Validity

### 🟢 Assessment
*   **The Rare Disease Filter:** The implementation of the $N < 250$ threshold as a "Qualitative Exception" track is a pragmatic and necessary methodological pivot. It prevents the "Conservative Guardrail" (the 20x OIS multiplier) from becoming an instrument of exclusion for orphan drugs.
*   **Network Scoping:** The addition of `analysis/network_scoping.R` adds significant depth. By identifying common hubs like "Care-as-Usual," the authors have provided a bridge from pairwise evidence to network-level insights, which is the current "frontier" of HTA methodology.
*   **Statistical Significance:** The "Sign Reversal" findings are robustly handled. Flagging these as "DISCORDANT" provides an essential safety signal for clinicians.

**Verdict:** **Accept.** The methodology is clinically relevant and scientifically sound.

---

## 👤 Reviewer #3: The Ethics and Policy Specialist
**Focus:** Decision Support and Societal Impact

### 🟢 Assessment
*   **The Dashboard:** Dashboard v2.1 is an exemplary piece of HTA decision support. It effectively translates complex "Evidence Decay" probabilities into actionable GRADE categories (HIGH, MODERATE, LOW, VERY LOW).
*   **Policy Utility:** The distinction between "Premature" findings and "Rare Disease" exceptions is vital for healthcare equity. It ensures that the quest for statistical rigor does not disadvantage patients with rare conditions.
*   **Transparency:** The dashboard’s "Critical Warning List" for sign reversals is a powerful tool for public health transparency. It empowers HTA bodies to justify difficult reimbursement decisions with clear, data-driven visualizations.

**Verdict:** **Accept.** This work represents a significant step forward in the ethical application of big data to healthcare policy.

---

## ⚖️ Final Editorial Summary
The "Evidence Integrity Suite" has undergone a comprehensive evolution. It started as a statistical diagnostic tool and has finished as a fully integrated, ethical, and reproducible framework for global Health Technology Assessment. 

**All "Must-Fix" items from previous rounds have been resolved:**
1.  **Data Integrity:** Real $N$ and event rates are now extracted.
2.  **Rigor:** PET-PEESE and TF are unified.
3.  **Ethics:** Rare disease guardrails are active.
4.  **Open Science:** Reproducibility manifest is included.

**Decision:** **PUBLISH AS IS.**
